Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$97.95
-$0.27(-0.64%)
At close: 4:00 PM EST
$97.95
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$43.30 - $114.99
Previous CloseN/A
Volume92.82K
Average Volume (3M)1.05M
Market Cap
$6.03B
Enterprise Value$4.95B
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jul 30, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume1,467,328
30 Day Avg. Volume1,049,849
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue8.69
Enterprise Value/Gross Profit10.68
Enterprise Value/Ebitda-129.11
Forecast
1Y Price Target
$144.50Price Target Upside47.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-15.6
Revenue Forecast (FY)$673.81M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst cites that volixibat produced a larger placebo-adjusted reduction in itch versus a competing bile acid transporter inhibitor in mid-stage data, indicating potential for superior symptomatic benefit if confirmed in pivotal studies.
Commercial PerformanceAnalyst highlights that reported product sales exceeded expectations driven by strong Livmarli demand and describes company sales guidance as conservative, implying upside if commercial momentum continues.
Product Formulation ExpansionAnalyst notes that approval of a tablet formulation for Livmarli in major markets could expand use beyond a pediatric liquid, simplify dosing for adults, and improve patient adherence leading to broader uptake.
Bears Say
Competition And Execution RiskAnalyst points out that a competing bile acid transporter inhibitor is further along in the regulatory process and that challenges in identifying eligible patients could constrain uptake and trial enrollment, creating commercial and execution risk.
Regulatory Pathway RiskAnalyst warns that regulators are likely to require a confirmatory late-stage study for pruritus approval, which could delay market access and extend development uncertainty.
Safety And TolerabilityAnalyst observes a somewhat higher rate of diarrhea with volixibat compared with a competitor, creating a tolerability risk that could affect patient retention and prescribing patterns.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $43.30 and its highest was $114.99 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $6.03B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 63 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$13.43 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$13.065.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.76.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$13.43 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -6.495%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$144.50 (47.52% Upside)
$144.50 (47.52% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 576.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.86%
12-Months-Change
Fundamentals
Return on Equity
-289.33%
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$144.50
▲(47.52% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
―
Ownership Overview
7.95% Insiders
25.66% Mutual Funds
48.40% Other Institutional Investors
5.04% Public Companies and
Individual Investors